Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02395627
Title Reversing Hormone Therapy Resistance With Epigenetic-Immune Modification
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Pamela Munster
Indications

estrogen-receptor positive breast cancer

Therapies

Pembrolizumab + Tamoxifen + Vorinostat

Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
University of California, San Francisco Medical Center San Francisco California 94115 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field